Showing results (381-390 of 5,984) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|August 24, 2017
Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer CellsChuay-Yeng Koo, Caterina Giacomini, Marta Reyes-Corral, et al.
Molecular Cancer Therapeutics|December 7, 2002
Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cellsKaterina Dvorakova, Claire M Payne, Margaret E Tome, et al.
Molecular Cancer Therapeutics|December 7, 2002
Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancersSanja Sale, Raphael Sung, Peidong Shen, et al.
Molecular Cancer Therapeutics|December 7, 2002
Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysisAkira Yokoi, Junro Kuromitsu, Takatoshi Kawai, et al.
Molecular Cancer Therapeutics|December 7, 2002
Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancerT K Bera, J Williams-Gould, R Beers, et al.
Molecular Cancer Therapeutics|December 7, 2002
Combination of thymidine phosphorylase gene transfer and deoxyinosine treatment greatly enhances 5-fluorouracil antitumor activity in vitro and in vivoJ Ciccolini, P Cuq, A Evrard, et al.
Molecular Cancer Therapeutics|December 7, 2002
Dual role of glutathione in modulating camptothecin activity: depletion potentiates activity, but conjugation enhances the stability of the topoisomerase I-DNA cleavage complexM P Gamcsik, M S Kasibhatla, D J Adams, et al.
Molecular Cancer Therapeutics|December 7, 2002
Inhibition of Kirsten-ras expression in human colorectal cancer using rationally selected Kirsten-ras antisense oligonucleotidesP J Ross, M George, D Cunningham, et al.
Molecular Cancer Therapeutics|December 7, 2002
Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDRK H Shain, W S Dalton
Molecular Cancer Therapeutics|August 27, 2003
Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumorsAndrey Frolov, Santiago Chahwan, Michael Ochs, et al.
Pageof 599